Zimmer Holdings’ planned takeover of hip manufacturer Biomet Inc. has been halted by the European Commission due to lack of information. Zimmer intends to purchase Biomet for more than $13 billion despite the number of Biomet hip replacement lawsuits filed against the company. The takeover of Biomet would make Zimmer the second-largest orthopedic manufacturer behind Johnson & Johnson, which also faces hip replacement lawsuits.
Biomet has recently come under fire for its M2a Magnum metal-on-metal hip replacement, which patients allege is causing serious injuries. A 2011 study of the M2a Magnum revealed that more than 7% of patients who receive the hip implant need revision surgery to remove it within one year, a revision rate much higher than expected.
Metal-on-metal hip replacement side effects have plagued patients for years, with thousands of hip implant lawsuits being filed against manufacturers, including Biomet. Patients complain of M2a Magnum side effects such as hip pain, limited mobility, premature loosening of the hip implant, and toxic levels of metal debris in the bloodstream, or “metallosis.”